Keppra
Primary Brain Tumor
Masonic Cancer Center, University of MinnesotaPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Primary Brain Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | BB |
(+)-VINCRISTINE H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | B |
Avutometinib Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Indoximod Theodore S. Johnson | Phase 1 | CC |
Ibrutinib Theodore S. Johnson | Phase 1 | CC |
ETOPOSIDE Theodore S. Johnson | Phase 1 | CC |
Cyclophosphamide Theodore S. Johnson | Phase 1 | CC |
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →